Financings in Brief: Abaxis
This article was originally published in The Gray Sheet
Abaxis: Nets $6.1 mil. from a private offering of 980,000 new common shares to a foreign investor. The blood analysis systems manufacturer says the proceeds will be used to commercialize its Piccolo portable blood analyzer and its VetScan veterinary products. Sunnyvale, California-based Abaxis recently entered a non-exclusive agreement with Baxter for distribution of the Piccolo, formerly known as the Epoc 2000, in the U.S. The system is scheduled for rollout in September, Abaxis says. The offering brings Abaxis' outstanding shares to 9.7 mil...
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.